Wall Street analysts initiated coverage on PPG, Shopify, Chesapeake Utilities, Global Payments and D

JP Morgan analyst Brian Cheng initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Ov

Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Tran

Citigroup analyst Samantha Semenkow initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) wit

NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:

NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:

Alyeska Investment Group L.P. increased its position in shares of Dianthus Therapeutics, Inc. (NASDA

Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by c

Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"

California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, In

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DN

Dimensional Fund Advisors LP lifted its position in Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 54

Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and r

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks

Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.90) per share which missed the

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pat

DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active

DNTH312 is an internally developed bifunctional fusion protein targeting potent inhibition of active

NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:

Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with

NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate cla

Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune

Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its C

Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's rilipr

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq:

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: D

Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy

Analysts change outlook on top names: Truist cut KFY price target, Oppenheimer raised AZO target, B.

Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about th

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

Dow falls 100 pts, Latham Group Inc (SWIM) rises 25.7%, Babcock & Wilcox Enterprises Inc (BW) ga

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company report